Henrik Sundin is a lawyer by training and has extensive experience from the financial sector. He has held CEO positions and served as a board member of several companies in this sector. Henrik Sundin is also an active investor in a number of companies. Henrik Sundin brings expertise in areas of business development, strategy and capital market issues to the company. Henrik has been an investor in Hamlet BioPharma since the company’s IPO.

An innovative pharmaceutical company with a broad and strong portfolio of projects for the treatment of cancer and infections.
Hamlet BioPharma AB
Klinikgatan 32
SE-222 42 Lund
info@hamletbiopharma.com
Org. no. 556568-8958
Subscribe to receive
Pressreleases and Newsletters
© 2026
Hamlet BioPharma.